ArticleEuropean urology open science2023
Prospective Trial of Water Vapor Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia in Subjects with a Large Prostate: 6- and 12-month Outcomes.
Article in European urology open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Predictors of surgical retreatment following Rezūm water vapor therapy: a multi-center real-world cohort study.World journal of urology · 2026Observational
- Water vapor thermotherapy and high-grade Clavien-Dindo complications: retrospective analysis of 10 cases.World journal of urology · 2026Article
- Water vapor thermal therapy for patients with large prostates (≥ 80 mL): initial real-world data from China.International urology and nephrology · 2026Article
- Impact of Prostatic Urethral Lift and Water Vapor Energy Therapy on Bladder Outlet Obstruction in Elderly or Comorbid Patients With Benign Prostatic Hyperplasia in Real-World Clinical Practice.Neurourology and urodynamics · 2026Article
- State-of-the-art in minimally invasive treatments for benign prostatic obstruction.Investigative and clinical urology · 2026Review
- Rezūm water vapor therapy vs. thulium laser enucleation for the treatment of benign prostatic hyperplasia in patients with large prostates: a multicenter prospective comparative study.Prostate cancer and prostatic diseases · 2025Article
- A comparative analysis of the outcomes of Rezūm therapy based on prostate size: a four-year retrospective analysis.World journal of urology · 2025Article
- Emphasis on the management of embedded capsular hyperplasia nodules associated with benign prostatic hyperplasia.Current urology · 2025Article
- To Rezūm or Not to Rezūm: A Narrative Review of Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia.Journal of clinical medicine · 2025Review
- Minimally invasive surgical techniques (MISTs) for benign prostatic hyperplasia: results from a Delphi consensus project to shed light on controversial topics.World journal of urology · 2025Article
- Real-world experience of water vapour therapy (Rezum) in patients with benign prostatic enlargement: a retrospective single-center study.Prostate cancer and prostatic diseases · 2025Article
- Expert consensus on Rezūm™: Indications, surgical technique and postoperative care.BJUI compass · 2025Review
- Water vapor thermal therapy for treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia (≥ 80 g).World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current guidelines recommend Rezūm water vapor thermal therapy for the treatment of benign prostatic hyperplasia (BPH) for prostate glands ranging in volume from 30 to 80 cm Objective: To evaluate the safety and efficacy of water vapor thermal therapy in patients with a prostate gland >80 cm Design setting and participants: In this prospective, single-arm study at seven centers in the USA, subjects were males aged >50 yr with symptomatic BPH and prostate volume of >80 cm Intervention: Rezūm was used to deliver sterile water vapor via a transurethral approach to ablate targeted areas of prostate tissue. Outcome measurements and statistical analysis: The primary efficacy outcome was response to therapy, defined on a per-patient basis as a ≥30% improvement in International Prostate Symptom Score (IPSS) from baseline to 6 mo. The primary safety outcome was a composite of serious device-related safety events. Secondary outcomes included catheterization for device-related retention. IPSS outcomes over time were analyzed via generalized estimating equations. Results and limitations: Among 47 eligible patients, prostate volume ranged from 80.8 to 148.1 cm Conclusions: Our results are consistent with previous findings for prostate glands of up to 80 cm Patient summary: Rezūm therapy, in which water vapor is used to treat targeted areas of the prostate, is currently recommended for patients with benign enlargement of the prostate and a prostate size of up to 80 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.